nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRFAM7A—corpus luteum—breast cancer	0.0565	0.272	CbGeAlD
Varenicline—CHRNA7—corpus luteum—breast cancer	0.0457	0.22	CbGeAlD
Varenicline—CHRNA6—skin of body—breast cancer	0.0103	0.0495	CbGeAlD
Varenicline—CHRNB2—nipple—breast cancer	0.00924	0.0444	CbGeAlD
Varenicline—CHRNA3—skin of body—breast cancer	0.00574	0.0276	CbGeAlD
Varenicline—CHRNB2—endometrium—breast cancer	0.00558	0.0268	CbGeAlD
Varenicline—CHRNB2—uterus—breast cancer	0.00514	0.0247	CbGeAlD
Varenicline—CHRNB2—pituitary gland—breast cancer	0.00505	0.0243	CbGeAlD
Varenicline—CHRNB2—adipose tissue—breast cancer	0.00503	0.0242	CbGeAlD
Varenicline—CHRNB2—adrenal gland—breast cancer	0.00451	0.0217	CbGeAlD
Varenicline—CHRNA3—adrenal gland—breast cancer	0.00437	0.021	CbGeAlD
Varenicline—CHRNB2—bone marrow—breast cancer	0.00436	0.021	CbGeAlD
Varenicline—CHRNB2—female gonad—breast cancer	0.0042	0.0202	CbGeAlD
Varenicline—CHRNA3—endocrine gland—breast cancer	0.00379	0.0182	CbGeAlD
Varenicline—CHRNA7—skin of body—breast cancer	0.00375	0.018	CbGeAlD
Varenicline—CHRFAM7A—female reproductive system—breast cancer	0.00362	0.0174	CbGeAlD
Varenicline—CHRFAM7A—female gonad—breast cancer	0.0033	0.0159	CbGeAlD
Varenicline—CHRNA7—uterus—breast cancer	0.00326	0.0157	CbGeAlD
Varenicline—CHRFAM7A—endocrine gland—breast cancer	0.00307	0.0147	CbGeAlD
Varenicline—CHRNA7—female reproductive system—breast cancer	0.00293	0.0141	CbGeAlD
Varenicline—CHRNA7—adrenal gland—breast cancer	0.00286	0.0137	CbGeAlD
Varenicline—CHRNA4—adrenal gland—breast cancer	0.00282	0.0135	CbGeAlD
Varenicline—CHRNB2—lymph node—breast cancer	0.0027	0.013	CbGeAlD
Varenicline—CHRNA7—female gonad—breast cancer	0.00266	0.0128	CbGeAlD
Varenicline—CHRNA3—lymph node—breast cancer	0.00262	0.0126	CbGeAlD
Varenicline—CHRNA7—endocrine gland—breast cancer	0.00248	0.0119	CbGeAlD
Varenicline—CHRNA4—endocrine gland—breast cancer	0.00244	0.0117	CbGeAlD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—DLX2—breast cancer	0.00104	0.0247	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PER3—breast cancer	0.000995	0.0237	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—KCNN4—breast cancer	0.000975	0.0233	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—KCNN4—breast cancer	0.000859	0.0205	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NR2F6—breast cancer	0.000846	0.0202	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—DLX2—breast cancer	0.000708	0.0169	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HADHB—breast cancer	0.0007	0.0167	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—YBX1—breast cancer	0.0007	0.0167	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ATF4—breast cancer	0.00069	0.0164	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CLDN4—breast cancer	0.00069	0.0164	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—THRB—breast cancer	0.000668	0.0159	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—KCNH1—breast cancer	0.000629	0.015	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—KCNN4—breast cancer	0.000618	0.0147	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—KCNN4—breast cancer	0.000587	0.014	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—DLX2—breast cancer	0.000577	0.0138	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.000576	0.0137	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—KCNH1—breast cancer	0.000553	0.0132	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NRIP1—breast cancer	0.000545	0.013	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.000485	0.0116	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—KCNN4—breast cancer	0.000478	0.0114	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HADHB—breast cancer	0.000478	0.0114	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—YBX1—breast cancer	0.000478	0.0114	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—THRB—breast cancer	0.000456	0.0109	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.000437	0.0104	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.000413	0.00984	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—KCNH1—breast cancer	0.000398	0.0095	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.000394	0.00939	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HADHB—breast cancer	0.00039	0.0093	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—YBX1—breast cancer	0.00039	0.0093	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—KCNH1—breast cancer	0.000378	0.00902	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—AHR—breast cancer	0.000378	0.00901	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—THRB—breast cancer	0.000372	0.00887	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—ACHE—breast cancer	0.000365	0.00871	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—GATA3—breast cancer	0.000361	0.0086	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CPT1A—breast cancer	0.000337	0.00803	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.000332	0.00791	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ESR2—breast cancer	0.000324	0.00772	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—ACHE—breast cancer	0.000322	0.00767	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.000321	0.00766	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—BCHE—breast cancer	0.000318	0.00759	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—KCNH1—breast cancer	0.000308	0.00735	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—EGR1—breast cancer	0.000303	0.00722	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TOP2A—breast cancer	0.0003	0.00716	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.000298	0.00712	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NCOA2—breast cancer	0.000289	0.00689	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—AR—breast cancer	0.000286	0.00682	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EZH2—breast cancer	0.000285	0.0068	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.000282	0.00672	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—BCHE—breast cancer	0.00028	0.00668	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—ACHE—breast cancer	0.00028	0.00668	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.00027	0.00645	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—COMT—breast cancer	0.000254	0.00607	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HES1—breast cancer	0.000251	0.006	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EGR1—breast cancer	0.000247	0.0059	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—ACHE—breast cancer	0.000246	0.00588	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—GATA3—breast cancer	0.000246	0.00588	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—BCHE—breast cancer	0.000244	0.00582	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.000243	0.0058	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—ACHE—breast cancer	0.000232	0.00552	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.00023	0.00548	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—COMT—breast cancer	0.000224	0.00534	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ESR2—breast cancer	0.000221	0.00528	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—ACHE—breast cancer	0.00022	0.00524	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—breast cancer	0.000216	0.00515	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—BCHE—breast cancer	0.000215	0.00512	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—SIRT1—breast cancer	0.000213	0.00508	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.000211	0.00502	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—EGR1—breast cancer	0.000207	0.00493	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TYMS—breast cancer	0.000206	0.00492	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NCOR1—breast cancer	0.000204	0.00487	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—BCHE—breast cancer	0.000202	0.00481	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—GATA3—breast cancer	0.000201	0.00479	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—AR—breast cancer	0.000195	0.00466	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—COMT—breast cancer	0.000195	0.00465	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—BCHE—breast cancer	0.000191	0.00457	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—breast cancer	0.00019	0.00454	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—breast cancer	0.000181	0.00432	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—breast cancer	0.00018	0.0043	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ESR2—breast cancer	0.00018	0.0043	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—ACHE—breast cancer	0.000179	0.00427	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—ACHE—breast cancer	0.000177	0.00423	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HES1—breast cancer	0.000172	0.0041	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—COMT—breast cancer	0.000172	0.00409	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—EGR1—breast cancer	0.000169	0.00402	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—ACHE—breast cancer	0.000168	0.00402	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—LEP—breast cancer	0.000168	0.004	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—BRAF—breast cancer	0.000162	0.00387	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—COMT—breast cancer	0.000161	0.00385	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CDK4—breast cancer	0.000161	0.00384	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—breast cancer	0.000159	0.0038	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—AR—breast cancer	0.000159	0.0038	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—breast cancer	0.000159	0.00379	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NOS2—breast cancer	0.000156	0.00373	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—BCHE—breast cancer	0.000156	0.00372	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—BCHE—breast cancer	0.000155	0.00369	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—COMT—breast cancer	0.000153	0.00365	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—BCHE—breast cancer	0.000147	0.0035	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.000144	0.00343	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—BRAF—breast cancer	0.000143	0.00341	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HES1—breast cancer	0.00014	0.00334	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—ACHE—breast cancer	0.000137	0.00327	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—breast cancer	0.000137	0.00327	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CXCL8—breast cancer	0.000137	0.00326	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MDM2—breast cancer	0.000136	0.00325	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—RAF1—breast cancer	0.000136	0.00323	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—SERPINE1—breast cancer	0.000132	0.00314	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL1B—breast cancer	0.000131	0.00313	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—breast cancer	0.000131	0.00312	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—breast cancer	0.00013	0.0031	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—JUN—breast cancer	0.000127	0.00303	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CTNNB1—breast cancer	0.000126	0.00301	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—COMT—breast cancer	0.000125	0.00298	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—BRAF—breast cancer	0.000124	0.00297	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—COMT—breast cancer	0.000124	0.00295	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MDM2—breast cancer	0.00012	0.00286	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—BCHE—breast cancer	0.00012	0.00285	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—RAF1—breast cancer	0.000119	0.00285	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.000117	0.0028	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—COMT—breast cancer	0.000117	0.0028	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—breast cancer	0.000115	0.00274	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—breast cancer	0.000114	0.00273	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—breast cancer	0.000111	0.00265	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—BRAF—breast cancer	0.00011	0.00261	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—breast cancer	0.000109	0.0026	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—breast cancer	0.000109	0.00259	CbGpPWpGaD
Varenicline—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000107	0.000142	CcSEcCtD
Varenicline—Cardiac disorder—Epirubicin—breast cancer	0.000107	0.000142	CcSEcCtD
Varenicline—Vomiting—Fluorouracil—breast cancer	0.000107	0.000142	CcSEcCtD
Varenicline—Dyspepsia—Docetaxel—breast cancer	0.000107	0.000142	CcSEcCtD
Varenicline—Insomnia—Capecitabine—breast cancer	0.000106	0.000141	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—breast cancer	0.000106	0.00253	CbGpPWpGaD
Varenicline—Hypoaesthesia—Doxorubicin—breast cancer	0.000106	0.000141	CcSEcCtD
Varenicline—Rash—Fluorouracil—breast cancer	0.000106	0.000141	CcSEcCtD
Varenicline—Dermatitis—Fluorouracil—breast cancer	0.000106	0.000141	CcSEcCtD
Varenicline—Decreased appetite—Docetaxel—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Hypersensitivity—Paclitaxel—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Headache—Fluorouracil—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Urinary tract disorder—Doxorubicin—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Oedema peripheral—Doxorubicin—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Dysgeusia—Methotrexate—breast cancer	0.000105	0.00014	CcSEcCtD
Varenicline—Gastrointestinal disorder—Docetaxel—breast cancer	0.000105	0.000139	CcSEcCtD
Varenicline—Connective tissue disorder—Doxorubicin—breast cancer	0.000105	0.000139	CcSEcCtD
Varenicline—Dyspnoea—Capecitabine—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—Fatigue—Docetaxel—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—Angiopathy—Epirubicin—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—MDM2—breast cancer	0.000104	0.00249	CbGpPWpGaD
Varenicline—Urethral disorder—Doxorubicin—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—Nausea—Irinotecan—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—Nausea—Mitoxantrone—breast cancer	0.000104	0.000139	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—RAF1—breast cancer	0.000104	0.00248	CbGpPWpGaD
Varenicline—Immune system disorder—Epirubicin—breast cancer	0.000104	0.000138	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—JUN—breast cancer	0.000104	0.00247	CbGpPWpGaD
Varenicline—Mediastinal disorder—Epirubicin—breast cancer	0.000104	0.000138	CcSEcCtD
Varenicline—Constipation—Docetaxel—breast cancer	0.000104	0.000138	CcSEcCtD
Varenicline—Pain—Docetaxel—breast cancer	0.000104	0.000138	CcSEcCtD
Varenicline—Back pain—Methotrexate—breast cancer	0.000103	0.000138	CcSEcCtD
Varenicline—Dyspepsia—Capecitabine—breast cancer	0.000103	0.000138	CcSEcCtD
Varenicline—Chills—Epirubicin—breast cancer	0.000103	0.000137	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—BRAF—breast cancer	0.000103	0.00246	CbGpPWpGaD
Varenicline—Arrhythmia—Epirubicin—breast cancer	0.000103	0.000137	CcSEcCtD
Varenicline—Visual impairment—Doxorubicin—breast cancer	0.000102	0.000137	CcSEcCtD
Varenicline—Asthenia—Paclitaxel—breast cancer	0.000102	0.000137	CcSEcCtD
Varenicline—Decreased appetite—Capecitabine—breast cancer	0.000102	0.000136	CcSEcCtD
Varenicline—Nausea—Gemcitabine—breast cancer	0.000101	0.000135	CcSEcCtD
Varenicline—Gastrointestinal disorder—Capecitabine—breast cancer	0.000101	0.000135	CcSEcCtD
Varenicline—Fatigue—Capecitabine—breast cancer	0.000101	0.000135	CcSEcCtD
Varenicline—Pruritus—Paclitaxel—breast cancer	0.000101	0.000135	CcSEcCtD
Varenicline—Vision blurred—Methotrexate—breast cancer	0.000101	0.000134	CcSEcCtD
Varenicline—Mental disorder—Epirubicin—breast cancer	0.000101	0.000134	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—breast cancer	0.000101	0.000134	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—PTEN—breast cancer	0.0001	0.00239	CbGpPWpGaD
Varenicline—Constipation—Capecitabine—breast cancer	0.0001	0.000134	CcSEcCtD
Varenicline—Pain—Capecitabine—breast cancer	0.0001	0.000134	CcSEcCtD
Varenicline—Erythema—Epirubicin—breast cancer	0.0001	0.000133	CcSEcCtD
Varenicline—Malnutrition—Epirubicin—breast cancer	0.0001	0.000133	CcSEcCtD
Varenicline—Feeling abnormal—Docetaxel—breast cancer	9.98e-05	0.000133	CcSEcCtD
Varenicline—Nausea—Fluorouracil—breast cancer	9.96e-05	0.000133	CcSEcCtD
Varenicline—Eye disorder—Doxorubicin—breast cancer	9.94e-05	0.000132	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—breast cancer	9.93e-05	0.00237	CbGpPWpGaD
Varenicline—Ill-defined disorder—Methotrexate—breast cancer	9.92e-05	0.000132	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—breast cancer	9.92e-05	0.000132	CcSEcCtD
Varenicline—Gastrointestinal pain—Docetaxel—breast cancer	9.9e-05	0.000132	CcSEcCtD
Varenicline—Anaemia—Methotrexate—breast cancer	9.88e-05	0.000132	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—breast cancer	9.87e-05	0.000132	CcSEcCtD
Varenicline—Flatulence—Epirubicin—breast cancer	9.86e-05	0.000131	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—MAPK8—breast cancer	9.81e-05	0.00234	CbGpPWpGaD
Varenicline—Dysgeusia—Epirubicin—breast cancer	9.8e-05	0.000131	CcSEcCtD
Varenicline—Diarrhoea—Paclitaxel—breast cancer	9.77e-05	0.00013	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—BRAF—breast cancer	9.77e-05	0.00233	CbGpPWpGaD
Varenicline—Back pain—Epirubicin—breast cancer	9.68e-05	0.000129	CcSEcCtD
Varenicline—Feeling abnormal—Capecitabine—breast cancer	9.66e-05	0.000129	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—breast cancer	9.65e-05	0.000129	CcSEcCtD
Varenicline—Malaise—Methotrexate—breast cancer	9.64e-05	0.000129	CcSEcCtD
Varenicline—Muscle spasms—Epirubicin—breast cancer	9.62e-05	0.000128	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—breast cancer	9.61e-05	0.000128	CcSEcCtD
Varenicline—Vertigo—Methotrexate—breast cancer	9.61e-05	0.000128	CcSEcCtD
Varenicline—Gastrointestinal pain—Capecitabine—breast cancer	9.58e-05	0.000128	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—breast cancer	9.58e-05	0.000128	CcSEcCtD
Varenicline—Abdominal pain—Docetaxel—breast cancer	9.57e-05	0.000128	CcSEcCtD
Varenicline—Body temperature increased—Docetaxel—breast cancer	9.57e-05	0.000128	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—COMT—breast cancer	9.56e-05	0.00228	CbGpPWpGaD
Varenicline—Chills—Doxorubicin—breast cancer	9.54e-05	0.000127	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TNF—breast cancer	9.51e-05	0.00227	CbGpPWpGaD
Varenicline—Arrhythmia—Doxorubicin—breast cancer	9.5e-05	0.000127	CcSEcCtD
Varenicline—Dizziness—Paclitaxel—breast cancer	9.44e-05	0.000126	CcSEcCtD
Varenicline—Vision blurred—Epirubicin—breast cancer	9.43e-05	0.000126	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CXCL8—breast cancer	9.34e-05	0.00223	CbGpPWpGaD
Varenicline—Cough—Methotrexate—breast cancer	9.33e-05	0.000124	CcSEcCtD
Varenicline—Mental disorder—Doxorubicin—breast cancer	9.32e-05	0.000124	CcSEcCtD
Varenicline—Urticaria—Capecitabine—breast cancer	9.31e-05	0.000124	CcSEcCtD
Varenicline—Ill-defined disorder—Epirubicin—breast cancer	9.28e-05	0.000124	CcSEcCtD
Varenicline—Body temperature increased—Capecitabine—breast cancer	9.27e-05	0.000124	CcSEcCtD
Varenicline—Abdominal pain—Capecitabine—breast cancer	9.27e-05	0.000124	CcSEcCtD
Varenicline—Convulsion—Methotrexate—breast cancer	9.26e-05	0.000123	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—breast cancer	9.26e-05	0.000123	CcSEcCtD
Varenicline—Erythema—Doxorubicin—breast cancer	9.26e-05	0.000123	CcSEcCtD
Varenicline—Anaemia—Epirubicin—breast cancer	9.25e-05	0.000123	CcSEcCtD
Varenicline—Agitation—Epirubicin—breast cancer	9.19e-05	0.000123	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—MDM2—breast cancer	9.18e-05	0.00219	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—RAF1—breast cancer	9.15e-05	0.00218	CbGpPWpGaD
Varenicline—Flatulence—Doxorubicin—breast cancer	9.12e-05	0.000122	CcSEcCtD
Varenicline—Chest pain—Methotrexate—breast cancer	9.1e-05	0.000121	CcSEcCtD
Varenicline—Arthralgia—Methotrexate—breast cancer	9.1e-05	0.000121	CcSEcCtD
Varenicline—Myalgia—Methotrexate—breast cancer	9.1e-05	0.000121	CcSEcCtD
Varenicline—Vomiting—Paclitaxel—breast cancer	9.08e-05	0.000121	CcSEcCtD
Varenicline—Dysgeusia—Doxorubicin—breast cancer	9.07e-05	0.000121	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	9.04e-05	0.000121	CcSEcCtD
Varenicline—Malaise—Epirubicin—breast cancer	9.02e-05	0.00012	CcSEcCtD
Varenicline—Rash—Paclitaxel—breast cancer	9.01e-05	0.00012	CcSEcCtD
Varenicline—Dermatitis—Paclitaxel—breast cancer	9e-05	0.00012	CcSEcCtD
Varenicline—Discomfort—Methotrexate—breast cancer	8.99e-05	0.00012	CcSEcCtD
Varenicline—Vertigo—Epirubicin—breast cancer	8.99e-05	0.00012	CcSEcCtD
Varenicline—Syncope—Epirubicin—breast cancer	8.97e-05	0.00012	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL1B—breast cancer	8.96e-05	0.00214	CbGpPWpGaD
Varenicline—Back pain—Doxorubicin—breast cancer	8.95e-05	0.000119	CcSEcCtD
Varenicline—Headache—Paclitaxel—breast cancer	8.95e-05	0.000119	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—breast cancer	8.94e-05	0.00213	CbGpPWpGaD
Varenicline—Hypersensitivity—Docetaxel—breast cancer	8.92e-05	0.000119	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—breast cancer	8.9e-05	0.000119	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—breast cancer	8.88e-05	0.00212	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—breast cancer	8.85e-05	0.00211	CbGpPWpGaD
Varenicline—Palpitations—Epirubicin—breast cancer	8.84e-05	0.000118	CcSEcCtD
Varenicline—Loss of consciousness—Epirubicin—breast cancer	8.79e-05	0.000117	CcSEcCtD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—breast cancer	8.75e-05	0.00209	CbGpPWpGaD
Varenicline—Cough—Epirubicin—breast cancer	8.73e-05	0.000116	CcSEcCtD
Varenicline—Vision blurred—Doxorubicin—breast cancer	8.72e-05	0.000116	CcSEcCtD
Varenicline—Asthenia—Docetaxel—breast cancer	8.69e-05	0.000116	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—JUN—breast cancer	8.68e-05	0.00207	CbGpPWpGaD
Varenicline—Convulsion—Epirubicin—breast cancer	8.67e-05	0.000116	CcSEcCtD
Varenicline—Infection—Methotrexate—breast cancer	8.67e-05	0.000116	CcSEcCtD
Varenicline—Hypertension—Epirubicin—breast cancer	8.64e-05	0.000115	CcSEcCtD
Varenicline—Hypersensitivity—Capecitabine—breast cancer	8.64e-05	0.000115	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MDM2—breast cancer	8.63e-05	0.00206	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CTNNB1—breast cancer	8.61e-05	0.00205	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—RAF1—breast cancer	8.6e-05	0.00205	CbGpPWpGaD
Varenicline—Ill-defined disorder—Doxorubicin—breast cancer	8.59e-05	0.000115	CcSEcCtD
Varenicline—Pruritus—Docetaxel—breast cancer	8.57e-05	0.000114	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—breast cancer	8.56e-05	0.000114	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—breast cancer	8.56e-05	0.000114	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—breast cancer	8.54e-05	0.000114	CcSEcCtD
Varenicline—Chest pain—Epirubicin—breast cancer	8.52e-05	0.000114	CcSEcCtD
Varenicline—Arthralgia—Epirubicin—breast cancer	8.52e-05	0.000114	CcSEcCtD
Varenicline—Myalgia—Epirubicin—breast cancer	8.52e-05	0.000114	CcSEcCtD
Varenicline—Agitation—Doxorubicin—breast cancer	8.51e-05	0.000113	CcSEcCtD
Varenicline—Anxiety—Epirubicin—breast cancer	8.49e-05	0.000113	CcSEcCtD
Varenicline—Nausea—Paclitaxel—breast cancer	8.48e-05	0.000113	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—breast cancer	8.48e-05	0.000113	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	8.46e-05	0.000113	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—breast cancer	8.44e-05	0.000112	CcSEcCtD
Varenicline—Discomfort—Epirubicin—breast cancer	8.42e-05	0.000112	CcSEcCtD
Varenicline—Asthenia—Capecitabine—breast cancer	8.41e-05	0.000112	CcSEcCtD
Varenicline—Malaise—Doxorubicin—breast cancer	8.35e-05	0.000111	CcSEcCtD
Varenicline—Dry mouth—Epirubicin—breast cancer	8.33e-05	0.000111	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—breast cancer	8.32e-05	0.000111	CcSEcCtD
Varenicline—Anorexia—Methotrexate—breast cancer	8.32e-05	0.000111	CcSEcCtD
Varenicline—Syncope—Doxorubicin—breast cancer	8.3e-05	0.000111	CcSEcCtD
Varenicline—Pruritus—Capecitabine—breast cancer	8.29e-05	0.000111	CcSEcCtD
Varenicline—Diarrhoea—Docetaxel—breast cancer	8.28e-05	0.00011	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MDM2—breast cancer	8.19e-05	0.00195	CbGpPWpGaD
Varenicline—Palpitations—Doxorubicin—breast cancer	8.18e-05	0.000109	CcSEcCtD
Varenicline—Oedema—Epirubicin—breast cancer	8.17e-05	0.000109	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—RAF1—breast cancer	8.16e-05	0.00195	CbGpPWpGaD
Varenicline—Hypotension—Methotrexate—breast cancer	8.15e-05	0.000109	CcSEcCtD
Varenicline—Loss of consciousness—Doxorubicin—breast cancer	8.14e-05	0.000108	CcSEcCtD
Varenicline—Infection—Epirubicin—breast cancer	8.11e-05	0.000108	CcSEcCtD
Varenicline—Cough—Doxorubicin—breast cancer	8.08e-05	0.000108	CcSEcCtD
Varenicline—Shock—Epirubicin—breast cancer	8.03e-05	0.000107	CcSEcCtD
Varenicline—Convulsion—Doxorubicin—breast cancer	8.02e-05	0.000107	CcSEcCtD
Varenicline—Diarrhoea—Capecitabine—breast cancer	8.02e-05	0.000107	CcSEcCtD
Varenicline—Nervous system disorder—Epirubicin—breast cancer	8.01e-05	0.000107	CcSEcCtD
Varenicline—Dizziness—Docetaxel—breast cancer	8.01e-05	0.000107	CcSEcCtD
Varenicline—Thrombocytopenia—Epirubicin—breast cancer	7.99e-05	0.000107	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—breast cancer	7.99e-05	0.000107	CcSEcCtD
Varenicline—Tachycardia—Epirubicin—breast cancer	7.97e-05	0.000106	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—BRAF—breast cancer	7.97e-05	0.0019	CbGpPWpGaD
Varenicline—Musculoskeletal discomfort—Methotrexate—breast cancer	7.95e-05	0.000106	CcSEcCtD
Varenicline—Skin disorder—Epirubicin—breast cancer	7.93e-05	0.000106	CcSEcCtD
Varenicline—Hyperhidrosis—Epirubicin—breast cancer	7.89e-05	0.000105	CcSEcCtD
Varenicline—Insomnia—Methotrexate—breast cancer	7.89e-05	0.000105	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—BRAF—breast cancer	7.89e-05	0.00188	CbGpPWpGaD
Varenicline—Arthralgia—Doxorubicin—breast cancer	7.88e-05	0.000105	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—breast cancer	7.88e-05	0.000105	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—breast cancer	7.88e-05	0.000105	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—breast cancer	7.85e-05	0.000105	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	7.83e-05	0.000104	CcSEcCtD
Varenicline—Discomfort—Doxorubicin—breast cancer	7.79e-05	0.000104	CcSEcCtD
Varenicline—Anorexia—Epirubicin—breast cancer	7.78e-05	0.000104	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—breast cancer	7.78e-05	0.000104	CcSEcCtD
Varenicline—Somnolence—Methotrexate—breast cancer	7.76e-05	0.000103	CcSEcCtD
Varenicline—Dizziness—Capecitabine—breast cancer	7.75e-05	0.000103	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—breast cancer	7.71e-05	0.000103	CcSEcCtD
Varenicline—Vomiting—Docetaxel—breast cancer	7.7e-05	0.000103	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—breast cancer	7.68e-05	0.000102	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6—breast cancer	7.68e-05	0.00183	CbGpPWpGaD
Varenicline—Rash—Docetaxel—breast cancer	7.63e-05	0.000102	CcSEcCtD
Varenicline—Hypotension—Epirubicin—breast cancer	7.63e-05	0.000102	CcSEcCtD
Varenicline—Dermatitis—Docetaxel—breast cancer	7.63e-05	0.000102	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CXCL8—breast cancer	7.61e-05	0.00182	CbGpPWpGaD
Varenicline—Decreased appetite—Methotrexate—breast cancer	7.58e-05	0.000101	CcSEcCtD
Varenicline—Headache—Docetaxel—breast cancer	7.58e-05	0.000101	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—breast cancer	7.58e-05	0.00181	CbGpPWpGaD
Varenicline—Oedema—Doxorubicin—breast cancer	7.56e-05	0.000101	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—breast cancer	7.53e-05	0.0001	CcSEcCtD
Varenicline—Fatigue—Methotrexate—breast cancer	7.52e-05	0.0001	CcSEcCtD
Varenicline—Infection—Doxorubicin—breast cancer	7.51e-05	0.0001	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—BRAF—breast cancer	7.49e-05	0.00179	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—HRAS—breast cancer	7.47e-05	0.00178	CbGpPWpGaD
Varenicline—Pain—Methotrexate—breast cancer	7.46e-05	9.95e-05	CcSEcCtD
Varenicline—Vomiting—Capecitabine—breast cancer	7.45e-05	9.94e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Epirubicin—breast cancer	7.44e-05	9.92e-05	CcSEcCtD
Varenicline—Shock—Doxorubicin—breast cancer	7.43e-05	9.91e-05	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—breast cancer	7.41e-05	9.88e-05	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—breast cancer	7.4e-05	9.86e-05	CcSEcCtD
Varenicline—Rash—Capecitabine—breast cancer	7.39e-05	9.85e-05	CcSEcCtD
Varenicline—Insomnia—Epirubicin—breast cancer	7.39e-05	9.85e-05	CcSEcCtD
Varenicline—Dermatitis—Capecitabine—breast cancer	7.38e-05	9.84e-05	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—breast cancer	7.37e-05	9.83e-05	CcSEcCtD
Varenicline—Headache—Capecitabine—breast cancer	7.34e-05	9.79e-05	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—breast cancer	7.34e-05	9.78e-05	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—breast cancer	7.3e-05	9.74e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL1B—breast cancer	7.3e-05	0.00174	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—breast cancer	7.29e-05	0.00174	CbGpPWpGaD
Varenicline—Dyspnoea—Epirubicin—breast cancer	7.28e-05	9.71e-05	CcSEcCtD
Varenicline—Somnolence—Epirubicin—breast cancer	7.26e-05	9.68e-05	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—breast cancer	7.2e-05	9.6e-05	CcSEcCtD
Varenicline—Nausea—Docetaxel—breast cancer	7.19e-05	9.59e-05	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—breast cancer	7.19e-05	9.59e-05	CcSEcCtD
Varenicline—Dyspepsia—Epirubicin—breast cancer	7.19e-05	9.58e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Methotrexate—breast cancer	7.13e-05	9.51e-05	CcSEcCtD
Varenicline—Decreased appetite—Epirubicin—breast cancer	7.1e-05	9.46e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—JUN—breast cancer	7.08e-05	0.00169	CbGpPWpGaD
Varenicline—Hypotension—Doxorubicin—breast cancer	7.06e-05	9.41e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Epirubicin—breast cancer	7.05e-05	9.4e-05	CcSEcCtD
Varenicline—Fatigue—Epirubicin—breast cancer	7.04e-05	9.39e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CTNNB1—breast cancer	7.02e-05	0.00167	CbGpPWpGaD
Varenicline—Constipation—Epirubicin—breast cancer	6.98e-05	9.31e-05	CcSEcCtD
Varenicline—Pain—Epirubicin—breast cancer	6.98e-05	9.31e-05	CcSEcCtD
Varenicline—Nausea—Capecitabine—breast cancer	6.96e-05	9.28e-05	CcSEcCtD
Varenicline—Urticaria—Methotrexate—breast cancer	6.93e-05	9.24e-05	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—breast cancer	6.9e-05	9.2e-05	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—breast cancer	6.9e-05	9.2e-05	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.88e-05	9.18e-05	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—breast cancer	6.85e-05	0.00163	CbGpPWpGaD
Varenicline—Insomnia—Doxorubicin—breast cancer	6.83e-05	9.11e-05	CcSEcCtD
Varenicline—Dyspnoea—Doxorubicin—breast cancer	6.74e-05	8.98e-05	CcSEcCtD
Varenicline—Feeling abnormal—Epirubicin—breast cancer	6.73e-05	8.97e-05	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—breast cancer	6.72e-05	8.95e-05	CcSEcCtD
Varenicline—Gastrointestinal pain—Epirubicin—breast cancer	6.68e-05	8.9e-05	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MDM2—breast cancer	6.67e-05	0.00159	CbGpPWpGaD
Varenicline—Dyspepsia—Doxorubicin—breast cancer	6.65e-05	8.87e-05	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—RAF1—breast cancer	6.65e-05	0.00159	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—MDM2—breast cancer	6.61e-05	0.00158	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—RAF1—breast cancer	6.59e-05	0.00157	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—HRAS—breast cancer	6.57e-05	0.00157	CbGpPWpGaD
Varenicline—Decreased appetite—Doxorubicin—breast cancer	6.57e-05	8.76e-05	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—breast cancer	6.52e-05	8.7e-05	CcSEcCtD
Varenicline—Fatigue—Doxorubicin—breast cancer	6.51e-05	8.68e-05	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TNF—breast cancer	6.5e-05	0.00155	CbGpPWpGaD
Varenicline—Urticaria—Epirubicin—breast cancer	6.49e-05	8.65e-05	CcSEcCtD
Varenicline—Constipation—Doxorubicin—breast cancer	6.46e-05	8.61e-05	CcSEcCtD
Varenicline—Pain—Doxorubicin—breast cancer	6.46e-05	8.61e-05	CcSEcCtD
Varenicline—Abdominal pain—Epirubicin—breast cancer	6.46e-05	8.61e-05	CcSEcCtD
Varenicline—Body temperature increased—Epirubicin—breast cancer	6.46e-05	8.61e-05	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—breast cancer	6.43e-05	8.57e-05	CcSEcCtD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—breast cancer	6.3e-05	0.0015	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—MDM2—breast cancer	6.27e-05	0.0015	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—IL6—breast cancer	6.27e-05	0.00149	CbGpPWpGaD
Varenicline—Asthenia—Methotrexate—breast cancer	6.26e-05	8.35e-05	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—RAF1—breast cancer	6.25e-05	0.00149	CbGpPWpGaD
Varenicline—Feeling abnormal—Doxorubicin—breast cancer	6.23e-05	8.3e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—breast cancer	6.18e-05	0.00147	CbGpPWpGaD
Varenicline—Gastrointestinal pain—Doxorubicin—breast cancer	6.18e-05	8.24e-05	CcSEcCtD
Varenicline—Pruritus—Methotrexate—breast cancer	6.17e-05	8.23e-05	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—BRAF—breast cancer	6.1e-05	0.00146	CbGpPWpGaD
Varenicline—Hypersensitivity—Epirubicin—breast cancer	6.02e-05	8.02e-05	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—breast cancer	6e-05	8e-05	CcSEcCtD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—breast cancer	5.98e-05	0.00143	CbGpPWpGaD
Varenicline—Abdominal pain—Doxorubicin—breast cancer	5.97e-05	7.96e-05	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—breast cancer	5.97e-05	7.96e-05	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—breast cancer	5.97e-05	7.96e-05	CcSEcCtD
Varenicline—Asthenia—Epirubicin—breast cancer	5.86e-05	7.81e-05	CcSEcCtD
Varenicline—Pruritus—Epirubicin—breast cancer	5.78e-05	7.7e-05	CcSEcCtD
Varenicline—Dizziness—Methotrexate—breast cancer	5.77e-05	7.69e-05	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—HRAS—breast cancer	5.72e-05	0.00136	CbGpPWpGaD
Varenicline—Diarrhoea—Epirubicin—breast cancer	5.59e-05	7.45e-05	CcSEcCtD
Varenicline—Hypersensitivity—Doxorubicin—breast cancer	5.57e-05	7.42e-05	CcSEcCtD
Varenicline—Vomiting—Methotrexate—breast cancer	5.55e-05	7.4e-05	CcSEcCtD
Varenicline—Rash—Methotrexate—breast cancer	5.5e-05	7.33e-05	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—breast cancer	5.5e-05	7.33e-05	CcSEcCtD
Varenicline—Headache—Methotrexate—breast cancer	5.47e-05	7.29e-05	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—breast cancer	5.42e-05	7.23e-05	CcSEcCtD
Varenicline—Dizziness—Epirubicin—breast cancer	5.4e-05	7.2e-05	CcSEcCtD
Varenicline—Pruritus—Doxorubicin—breast cancer	5.35e-05	7.13e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TNF—breast cancer	5.3e-05	0.00126	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6—breast cancer	5.25e-05	0.00125	CbGpPWpGaD
Varenicline—Vomiting—Epirubicin—breast cancer	5.19e-05	6.92e-05	CcSEcCtD
Varenicline—Nausea—Methotrexate—breast cancer	5.18e-05	6.91e-05	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—breast cancer	5.17e-05	6.89e-05	CcSEcCtD
Varenicline—Rash—Epirubicin—breast cancer	5.15e-05	6.86e-05	CcSEcCtD
Varenicline—Dermatitis—Epirubicin—breast cancer	5.14e-05	6.86e-05	CcSEcCtD
Varenicline—Headache—Epirubicin—breast cancer	5.12e-05	6.82e-05	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—MDM2—breast cancer	5.11e-05	0.00122	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—RAF1—breast cancer	5.1e-05	0.00122	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—HRAS—breast cancer	5.04e-05	0.0012	CbGpPWpGaD
Varenicline—Dizziness—Doxorubicin—breast cancer	5e-05	6.66e-05	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—breast cancer	4.87e-05	0.00116	CbGpPWpGaD
Varenicline—Nausea—Epirubicin—breast cancer	4.85e-05	6.47e-05	CcSEcCtD
Varenicline—Vomiting—Doxorubicin—breast cancer	4.8e-05	6.4e-05	CcSEcCtD
Varenicline—Rash—Doxorubicin—breast cancer	4.76e-05	6.35e-05	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—breast cancer	4.76e-05	6.35e-05	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—HRAS—breast cancer	4.73e-05	0.00113	CbGpPWpGaD
Varenicline—Headache—Doxorubicin—breast cancer	4.73e-05	6.31e-05	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—HRAS—breast cancer	4.49e-05	0.00107	CbGpPWpGaD
Varenicline—Nausea—Doxorubicin—breast cancer	4.49e-05	5.98e-05	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6—breast cancer	4.28e-05	0.00102	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—HRAS—breast cancer	3.66e-05	0.000873	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—HRAS—breast cancer	3.63e-05	0.000865	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—HRAS—breast cancer	3.44e-05	0.000821	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—HRAS—breast cancer	2.81e-05	0.000669	CbGpPWpGaD
